 |
|
Clinical Experience with the Anticoagulant Acenocoumarin (Sintrom)
FRANCE ALEXANDER, M.D.;
J. L. KOPPEL, Ph.D.;
P. M. ARSCOTT, M.A.;
JOHN H. OLWIN, M.D.
AMA Arch Intern Med. 1957;100(4):558-564.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Thromboembolism and thromboembolic diseased states continue to be one of the major problems of clinical medicine. The potential hazards of thrombotic episodes and the frequent sequelae of chronic phlebitic processes render the effective use of anticoagulant drugs an increasingly important part of the clinician's therapeutic armamentarium. Such use is dependent upon the availability of anticoagulant drugs with clinically dependable pharmacological properties and on reliable assay procedures by which therapy with such drugs can be followed and controlled. A number of prothrombin depressants have been developed in the past 15 years, and of these, acenocoumarin (Sintrom) is one of the more recent ones. It is a nonhygroscopic light crystalline powder which is odorless and tasteless and is supplied for clinical use as 4 mg. scored tablets. It is stable under normal storage conditions and reacts as a weak acid. Chemically it is 3-( acetonyl-4-nitro-benzyl) 4-hydroxycoumarin.
Previous reports on acenocoumarin have described
. . . [Full Text PDF of this Article]
Author Affiliations
Chicago
From the Department of Surgery, Presbyterian-St. Luke's Hospital. Affiliated with the University of Illinois College of Medicine.
Footnotes
Submitted for publication March 11, 1957.
This study was supported by funds from the Anna L. and Arthur Dean Bevan Trust and funds from Mrs. Cleona McAdoo and Geigy Pharmaceuticals, Ardsley, N. Y.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
|
